Kevin R. Regner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kevin R. Regner has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Frank Park
College of Pharmacy, Department of Pharmaceutical Sciences University of Tennessee Health Sciences Center Memphis Tennessee USA
5 shared publications Sarah M. White
Department of Medicine, Division of Nephrology (S.M.W., L.M.N., E.H., M.G., K.R.R.), Cardiovascular Research Center (K.R.R.), Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Pharmaceutical Sciences, University of Tennessee Health Sciences Center, Memphis, Tennessee (J.D.P., F.P.); and Department of Physiology, University of South Alabama, Mobile, Alabama (L.M.S., D.S.W.)
2 shared publications- Aaron T. Dall
Department of Medicine, Division of Nephrology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA
1 shared publication - Abhilash Koratala
Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin
1 shared publication - Andrew S. Allegretti
Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA
1 shared publication - Andrey Sorokin
Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States
1 shared publication
Latest Publications
- Open Access
- 19 November 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (11) , 2416-2417
Tubular Secretion, Glomerular Function, and the Long Arc to Heart Failure–Associated Acute Kidney Injury
- 19 November 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (11) , 2416-2417
Open AccessTubular Secretion, Glomerular Function, and the Long Arc to Heart Failure–Associated Acute Kidney Injury
- 29 May 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (10) , E38-E39
Letter to the Editor: Point-of-care ultrasound in cirrhosis-related acute kidney injury: A cautionary note
- 29 May 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (10) , E38-E39
Letter to the Editor: Point-of-care ultrasound in cirrhosis-related acute kidney injury: A cautionary note
- 30 August 2023
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 30 (4) , 307-314
Update on Assessment of Estimated Glomerular Filtration Rate in Patients With Cirrhosis
- 30 August 2023
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 30 (4) , 307-314
Update on Assessment of Estimated Glomerular Filtration Rate in Patients With Cirrhosis
- 1 August 2023
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 325 (2) , F248-F261
Identification of cell division cycle protein 20 in various forms of acute and chronic kidney injury in mice
To our knowledge, this is the first study to characterize the expression and localization of cell division cycle 20 protein (CDC20) in normal and acute, and chronically injured kidneys. Tubular epithelial cell damage was markedly reduced through the administration of a selective inhibitor of CDC20, Apcin. This study provides new evidence that CDC20 can be induced in damaged kidney cells and negatively impact the recovery of the kidney following acute kidney injury.
- 1 August 2023
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 325 (2) , F248-F261
Identification of cell division cycle protein 20 in various forms of acute and chronic kidney injury in mice
To our knowledge, this is the first study to characterize the expression and localization of cell division cycle 20 protein (CDC20) in normal and acute, and chronically injured kidneys. Tubular epithelial cell damage was markedly reduced through the administration of a selective inhibitor of CDC20, Apcin. This study provides new evidence that CDC20 can be induced in damaged kidney cells and negatively impact the recovery of the kidney following acute kidney injury.
- Open Access
- 10 February 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (4) , e448-e456
Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
Key Points: Raising the mean arterial pressure (MAP) during management of hepatorenal syndrome type 1 (HRS-1) is associated with improvement in kidney function, independently of baseline MAP or model for end-stage liver disease. Raising the MAP by 15 mm Hg or greater leads to greater reduction in serum creatinine in HRS-1. Norepinephrine use confers greater probability of improvement in kidney function in HRS-1 compared with midodrine/octreotide. Background: Raising mean arterial pressure (MAP) during treatment of hepatorenal syndrome type 1 (HRS-1) with vasoconstrictors (VCs) is associated with renal recovery. However, the optimal MAP target and factors associated with response to VCs remain unclear. Methods: Records from hospitalized patients with HRS-1 treated with VCs without shock were reviewed searching for those who achieved ≥5 mm Hg rise in MAP within 48 hours. We examined the relationship between the mean MAP achieved during the first 48–72 hours of VC therapy and the change in serum creatinine (sCr) up to day 14. Endpoints were >30% reduction in sCr without need for dialysis or death by day 14 (primary) or by day 30 (secondary). Results: Seventy-seven patients with HRS-1 treated for 2–10 days with either norepinephrine (n=49) or midodrine/octreotide (n=28) were included. The median age was 52 years (interquartile range [IQR], 46–60), 40% were female, and 48% had alcoholic cirrhosis. At VC initiation, median MAP was 70 mm Hg (IQR, 66–73), and median sCr was 3.8 mg/dl (IQR, 2.6–4.9). When analyzed by tertiles of mean MAP increment (5–9, 10–14, ≥15 mm Hg), there was greater reduction in sCr with greater rise in MAP (ANOVA for trend, P < 0.0001). By multivariate logistic regression analysis, mean MAP rise during the first 48–72 hours (odds ratio [OR], 1.15 [1.02 to 1.299], P=0.025), norepinephrine as VC (OR, 5.46 [1.36 to 21.86], P=0.017), and baseline sCr [OR, 0.63 [0.41 to 0.97], P=0.034) were associated with the primary endpoint, whereas mean MAP rise during the first 48–72 hours (OR, 1.17 [1.04 to 1.33], P=0.012) and baseline sCr (OR, 0.63 [0.39 to 0.98], P=0.043) were associated with the secondary endpoint. Conclusions: Greater magnitude of rise in MAP with VC therapy in HRS-1, lower baseline sCr, and use of norepinephrine over midodrine/octreotide are associated with kidney recovery. Targeting an increment of MAP ≥15 mm Hg may lead to favorable renal outcomes.
- 10 February 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (4) , e448-e456
Open AccessResponsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
Key Points: Raising the mean arterial pressure (MAP) during management of hepatorenal syndrome type 1 (HRS-1) is associated with improvement in kidney function, independently of baseline MAP or model for end-stage liver disease. Raising the MAP by 15 mm Hg or greater leads to greater reduction in serum creatinine in HRS-1. Norepinephrine use confers greater probability of improvement in kidney function in HRS-1 compared with midodrine/octreotide. Background: Raising mean arterial pressure (MAP) during treatment of hepatorenal syndrome type 1 (HRS-1) with vasoconstrictors (VCs) is associated with renal recovery. However, the optimal MAP target and factors associated with response to VCs remain unclear. Methods: Records from hospitalized patients with HRS-1 treated with VCs without shock were reviewed searching for those who achieved ≥5 mm Hg rise in MAP within 48 hours. We examined the relationship between the mean MAP achieved during the first 48–72 hours of VC therapy and the change in serum creatinine (sCr) up to day 14. Endpoints were >30% reduction in sCr without need for dialysis or death by day 14 (primary) or by day 30 (secondary). Results: Seventy-seven patients with HRS-1 treated for 2–10 days with either norepinephrine (n=49) or midodrine/octreotide (n=28) were included. The median age was 52 years (interquartile range [IQR], 46–60), 40% were female, and 48% had alcoholic cirrhosis. At VC initiation, median MAP was 70 mm Hg (IQR, 66–73), and median sCr was 3.8 mg/dl (IQR, 2.6–4.9). When analyzed by tertiles of mean MAP increment (5–9, 10–14, ≥15 mm Hg), there was greater reduction in sCr with greater rise in MAP (ANOVA for trend, P < 0.0001). By multivariate logistic regression analysis, mean MAP rise during the first 48–72 hours (odds ratio [OR], 1.15 [1.02 to 1.299], P=0.025), norepinephrine as VC (OR, 5.46 [1.36 to 21.86], P=0.017), and baseline sCr [OR, 0.63 [0.41 to 0.97], P=0.034) were associated with the primary endpoint, whereas mean MAP rise during the first 48–72 hours (OR, 1.17 [1.04 to 1.33], P=0.012) and baseline sCr (OR, 0.63 [0.39 to 0.98], P=0.043) were associated with the secondary endpoint. Conclusions: Greater magnitude of rise in MAP with VC therapy in HRS-1, lower baseline sCr, and use of norepinephrine over midodrine/octreotide are associated with kidney recovery. Targeting an increment of MAP ≥15 mm Hg may lead to favorable renal outcomes.
- 3 March 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 603, 69-74
p66Shc signaling does not contribute to tubular damage induced by renal ischemia-reperfusion injury in rat
- 3 March 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 603, 69-74
p66Shc signaling does not contribute to tubular damage induced by renal ischemia-reperfusion injury in rat
- Open Access
- 22 November 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (22)
DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity
Cisplatin is a commonly used chemotherapeutic agent to treat a wide array of cancers that is frequently associated with toxic injury to the kidney due to oxidative DNA damage and perturbations in cell cycle progression leading to cell death. In this study, we investigated whether thyroid receptor interacting protein 13 (TRIP13) plays a central role in the protection of the tubular epithelia following cisplatin treatment by circumventing DNA damage. Following cisplatin treatment, double-stranded DNA repair pathways were inhibited using selective blockers to proteins involved in either homologous recombination or non-homologous end joining. This led to increased blood markers of acute kidney injury (AKI) (creatinine and neutrophil gelatinase–associated lipocalin), tubular damage, activation of DNA damage marker (γ-H2AX), elevated appearance of G2/M blockade (phosphorylated histone H3 Ser10 and cyclin B1), and apoptosis (cleaved caspase-3). Conditional proximal tubule–expressing Trip13 mice were observed to be virtually protected from the cisplatin nephrotoxicity by restoring most of the pathological phenotypes back toward normal conditions. Our findings suggest that TRIP13 could circumvent DNA damage in the proximal tubules during cisplatin injury and that TRIP13 may constitute a new therapeutic target in protecting the kidney from nephrotoxicants and reduce outcomes leading to AKI.
- 22 November 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (22)
Open AccessDNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity
Cisplatin is a commonly used chemotherapeutic agent to treat a wide array of cancers that is frequently associated with toxic injury to the kidney due to oxidative DNA damage and perturbations in cell cycle progression leading to cell death. In this study, we investigated whether thyroid receptor interacting protein 13 (TRIP13) plays a central role in the protection of the tubular epithelia following cisplatin treatment by circumventing DNA damage. Following cisplatin treatment, double-stranded DNA repair pathways were inhibited using selective blockers to proteins involved in either homologous recombination or non-homologous end joining. This led to increased blood markers of acute kidney injury (AKI) (creatinine and neutrophil gelatinase–associated lipocalin), tubular damage, activation of DNA damage marker (γ-H2AX), elevated appearance of G2/M blockade (phosphorylated histone H3 Ser10 and cyclin B1), and apoptosis (cleaved caspase-3). Conditional proximal tubule–expressing Trip13 mice were observed to be virtually protected from the cisplatin nephrotoxicity by restoring most of the pathological phenotypes back toward normal conditions. Our findings suggest that TRIP13 could circumvent DNA damage in the proximal tubules during cisplatin injury and that TRIP13 may constitute a new therapeutic target in protecting the kidney from nephrotoxicants and reduce outcomes leading to AKI.
- 29 April 2021
- Published by Wolters Kluwer Health in Kidney360
- Vol. 2 (4) , 619-628
AKI in Hospitalized Patients with COVID-19 and Seasonal Influenza: A Comparative Analysis
Key Points: The rate of AKI is similar in COV-AKI and FLU-AKI, although risk of stage 3 AKI is higher in COV-AKI and is associated with a poorer prognosis. Black race and mechanical ventilation are associated with a higher risk of COV-AKI. CKD is a major risk factor for AKI in both groups. COV-AKI is associated with a 2.3-fold higher odds of proteinuria 2+ or more in comparison with FLU-AKI. Background: Coronavirus disease 2019 (COVID-19) is often compared with seasonal influenza and the two diseases have similarities, including the risk of systemic manifestations such as AKI. The aim of this study was to perform a comparative analysis of the prevalence, risk factors, and outcomes of AKI in patients who were hospitalized with COVID-19 and influenza. Methods: Retrospective cohort study of patients who were hospitalized with COVID-19 (n=325) or seasonal influenza (n=433). AKI was defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Baseline characteristics and hospitalization data were collected, and multivariable analysis was performed to determine the independent predictors for AKI. Results: AKI occurred in 33% of COVID-19 hospitalizations (COV-AKI) and 33% of influenza hospitalizations (FLU-AKI). After adjusting for age, sex, and comorbidity count, the risk of stage 3 AKI was significantly higher in COV-AKI (OR, 3.46; 95% CI, 1.63 to 7.37). Pre-existing CKD was associated with a six- to seven-fold increased likelihood for FLU-AKI and COV-AKI. Mechanical ventilation was associated with a higher likelihood of developing AKI in the COVID-19 cohort (OR, 5.85; 95% CI, 2.30 to 15.63). Black race, after adjustment for comorbidities, was an independent risk for COV-AKI. Conclusions: Pre-existing CKD was a major risk factor for AKI in both cohorts. Black race (independent of comorbidities) and mechanical ventilation were associated with a higher risk of developing COV-AKI, which is characterized by a higher burden of stage 3 AKI and overall poorer prognosis.
- 29 April 2021
- Published by Wolters Kluwer Health in Kidney360
- Vol. 2 (4) , 619-628
AKI in Hospitalized Patients with COVID-19 and Seasonal Influenza: A Comparative Analysis
Key Points: The rate of AKI is similar in COV-AKI and FLU-AKI, although risk of stage 3 AKI is higher in COV-AKI and is associated with a poorer prognosis. Black race and mechanical ventilation are associated with a higher risk of COV-AKI. CKD is a major risk factor for AKI in both groups. COV-AKI is associated with a 2.3-fold higher odds of proteinuria 2+ or more in comparison with FLU-AKI. Background: Coronavirus disease 2019 (COVID-19) is often compared with seasonal influenza and the two diseases have similarities, including the risk of systemic manifestations such as AKI. The aim of this study was to perform a comparative analysis of the prevalence, risk factors, and outcomes of AKI in patients who were hospitalized with COVID-19 and influenza. Methods: Retrospective cohort study of patients who were hospitalized with COVID-19 (n=325) or seasonal influenza (n=433). AKI was defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Baseline characteristics and hospitalization data were collected, and multivariable analysis was performed to determine the independent predictors for AKI. Results: AKI occurred in 33% of COVID-19 hospitalizations (COV-AKI) and 33% of influenza hospitalizations (FLU-AKI). After adjusting for age, sex, and comorbidity count, the risk of stage 3 AKI was significantly higher in COV-AKI (OR, 3.46; 95% CI, 1.63 to 7.37). Pre-existing CKD was associated with a six- to seven-fold increased likelihood for FLU-AKI and COV-AKI. Mechanical ventilation was associated with a higher likelihood of developing AKI in the COVID-19 cohort (OR, 5.85; 95% CI, 2.30 to 15.63). Black race, after adjustment for comorbidities, was an independent risk for COV-AKI. Conclusions: Pre-existing CKD was a major risk factor for AKI in both cohorts. Black race (independent of comorbidities) and mechanical ventilation were associated with a higher risk of developing COV-AKI, which is characterized by a higher burden of stage 3 AKI and overall poorer prognosis.
- 25 March 2021
- Published by Wolters Kluwer Health in Kidney360
- Vol. 2 (3) , 413-414
Patients with Hepatorenal Syndrome Should Be Dialyzed? COMMENTARY
This is an Early Access article. Please select the PDF button, above, to view it. Be sure to also read the PRO: 10.34067/KID.0006952020 and the CON: 10.34067/KID.0006872020
- 25 March 2021
- Published by Wolters Kluwer Health in Kidney360
- Vol. 2 (3) , 413-414
Patients with Hepatorenal Syndrome Should Be Dialyzed? COMMENTARY
This is an Early Access article. Please select the PDF button, above, to view it. Be sure to also read the PRO: 10.34067/KID.0006952020 and the CON: 10.34067/KID.0006872020
- Open Access
- 7 June 2018
- Published by Springer Nature in BMC Research Notes
- Vol. 11 (1) , 1-6
Urinary exosomal expression of activator of G protein signaling 3 in polycystic kidney disease
PKD is a genetic disease that is characterized by abnormally proliferative epithelial cells in the kidney and liver. Urinary exosomes have been previously examined as a source of unique proteins that may be used to diagnose and monitor the progression of PKD. Previous studies by our group have shown that AGS3, which is a receptor-independent regulator G-proteins, was markedly upregulated in RTECs during kidney injury including PKD. In this study, our goal was to determine whether AGS3 could be measured in exosomes using animals and humans with PKD. In our study, urinary exosomes were isolated from PCK rats and the control Sprague–Dawley (SD) rats. AGS3 expression was significantly increased (P < 0.05) in PKD versus SD rats at 16 weeks of age. This increase was detectable in a time-dependent manner from 8 weeks of age and peaked at ~ 16–20 weeks (length of study). Similarly, in exosomes from human urine samples with PKD, AGS3 expression was significantly increased (P < 0.05) compared to healthy human controls where AGS3 was largely undetectable. In conclusion, the detection of AGS3 in urinary exosomes may be a novel biomarker for PKD, and provide new insight into the biology of tubular epithelial cell function during cystic disease progression.
- 7 June 2018
- Published by Springer Nature in BMC Research Notes
- Vol. 11 (1) , 1-6
Open AccessUrinary exosomal expression of activator of G protein signaling 3 in polycystic kidney disease
PKD is a genetic disease that is characterized by abnormally proliferative epithelial cells in the kidney and liver. Urinary exosomes have been previously examined as a source of unique proteins that may be used to diagnose and monitor the progression of PKD. Previous studies by our group have shown that AGS3, which is a receptor-independent regulator G-proteins, was markedly upregulated in RTECs during kidney injury including PKD. In this study, our goal was to determine whether AGS3 could be measured in exosomes using animals and humans with PKD. In our study, urinary exosomes were isolated from PCK rats and the control Sprague–Dawley (SD) rats. AGS3 expression was significantly increased (P < 0.05) in PKD versus SD rats at 16 weeks of age. This increase was detectable in a time-dependent manner from 8 weeks of age and peaked at ~ 16–20 weeks (length of study). Similarly, in exosomes from human urine samples with PKD, AGS3 expression was significantly increased (P < 0.05) compared to healthy human controls where AGS3 was largely undetectable. In conclusion, the detection of AGS3 in urinary exosomes may be a novel biomarker for PKD, and provide new insight into the biology of tubular epithelial cell function during cystic disease progression.